41.67USD+0.31%Mkt Cap: 2.55B USDP/E: —Last update: 2026-05-26
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.55B USD
Enterprise Value2.12B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-103.69M USD
Revenue/Share—
Last Price41.67 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees61
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-17.73
PEG—
EV/EBITDA-18.35
EV/Revenue—
P/S—
P/B5.67
EPS (TTM)-1.64
EPS (Forward)-2.38
52W Range
14.7980% of range48.53
52W High48.53 USD
52W Low14.79 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.56%
ROA-21.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-70.30M USD
CapEx (TTM)158.00K USD
FCF Margin—
FCF Yield-1.81%
Net Debt-452.10M USD
Net Debt/EBITDA3.91
Balance Sheet
Debt/Equity0.00
Current Ratio40.32
Quick Ratio39.38
Book Value/Sh7.446 USD
Cash/Share7.428 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)57.00 USD
Target Range45.00 USD – 80.00 USD
# Analysts8
Ownership
Shares Out.60.90M
Float44.42M
Insiders7.52%
Institutions105.00%
Short Interest
Short Ratio4.7d
Short % Float13.70%
Short % Out.8.66%
Shares Short5.27M
Short (prev mo.)6.05M
Technical
SMA 5039.71 (+4.9%)
SMA 20026.34 (+58.2%)
Beta0.45
S&P 52W Chg28.31%
Avg Vol (30d)700.76K
Avg Vol (10d)742.84K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—